Updates on the respiratory therapeutic market.
The respiratory therapeutic market comprises various diseases including asthma, bronchial disease, cystic fibrosis, a genetic disease with respiratory and digestive disease components, COPD, and the common cold. Of these, asthma and COPD comprise a $32 billion global market according to IMS 2009 data, with asthma valued at $15 billion in the United States and COPD valued at $4 billion to $5 billion. However, current asthma and COPD products are facing a patent protection expiry by 2016, and include Advair (GlaxoSmithKline), Symbicort (AstraZeneca), Singulair (Merck), and Spiriva (Boehringer Ingelheim).
In 2016, many therapeutic areas and pharmaceutical companies will be affected by the same patent cliff. However, Advair is projected to retain a number nine for global sales that year, with a negative (-)6% annual growth between 2009 and 2016, the year of its expiration.
Respiratory Studies Snapshot
Future market growth in asthma and COPD will be driven by a growing disease awareness, and thus patient pool, and the launch of newer, more expensive therapies. This growth will be tempered by new generics and the decrease of monotherapy product sales by combination drugs. This market information comes from a press release issued by Sandoz on its announcement of acquiring Oriel Therapeutics, a privately held U.S.-based pharmaceutical company focusing on respiratory products.
In the meantime, in regard to clinical trials, issues around data collection are important, as in any therapeutic area. OmniComm Systems recently reported successful use of its EDC and trial management software for medical device company Asthmatx. Its AIR2 Trial collected nearly 6GB of data and included 30 active sites in six countries. Two hundred ninety-seven adult subjects were enrolled and the trial collected over 77,000 forms from 12 office visits and 31 phone contacts per subject. Case Report Form (CRF) design included 1869 edit specifications. The system was also required to import data from electronic daily diaries maintained by study subjects. This electronic patient reported outcomes (ePRO) was fulfilled by PHT.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.